Exercise Neuroprotection in Parkinson's Disease
University of Nevada, Las Vegas · NCT05854524
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 30–85 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 90
- US sites recruiting
- 1
- Study start
- August 29, 2024
- Record last updated
- September 3, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to explore the relationships of exercise on inflammation in the body of older adults and people with Parkinson's disease (PD). This is important research for older adults but is especially important for people with PD because neuroinflammation is the main pathological mechanism that is responsible for neuron cell death in this neurodegenerative disease. As PD is a progressive disease, halting or slowing the degeneration is an important research target. Halting or slowing the disease progress is known as neuroprotection. Exercise is an attractive therapeutic treatment for people with PD as it has a lot of multi-systemic benefits, but also there is a lot of evidence to suggest that it helps improve symptoms and slow the progression of the disease. Exercise has been theorized to decrease inflammation and, therefore, has a lot of promise as a neuroprotective agent in slowing or halting the degeneration in PD. Unfortunately, there is not a lot of research that has looked into the effect of exercise on the biological processes of inflammation. Thus, the purpose of this study is to investigate the biological evidence that underlies the positive effect of exercise in people with PD.
Being studied: Aerobic exercise
Conditions: Parkinson Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria for PwP
- 30-85 years old
- Neurologist-diagnosed PD
- Able to participate in 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks per self-report.
Inclusion criteria for controls
- 30-85 years old
- No major medical diagnoses
- Able to participate in 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks per self-report.
Exclusion Criteria for both PD group and controls:
- Diagnoses, identified by self-report, that would preclude exercise participation (e.g., heart arrhythmias, uncontrolled blood pressure, exercise-induced asthma).
- Those not deemed ready for exercise participation. Participants will be screened for exercise participation using the Physical Activities Readiness Questionnaire + which is used as a screening tool for all ages to identify risk factors that would clear someone for participation in moderate physical exercise.
- Those with dementia will be excluded because there are self-report questionnaires in this study. This will be identified using the Montreal Cognitive Assessment and a score at or below a 21. Participants with mild cognitive impairment and no impairment will be included.
Recruiting US locations
Gait and Balance Laboratory, 217 Bigelow Health Sciences Building, UNLV
Las Vegas, NV 89154
Site contact: Merrill Landers, PT, DPT, PhD · 7028951377 · merrill.landers@unlv.edu
Study contacts (from the official record)
- Merrill Landers, DPT, PhD · 17028951377 · merrill.landers@unlv.edu
Similar studies in Nevada
All neurology studies in Nevada →- RecruitingHealthy volunteers
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment…
GAP Innovations, PBC
- Location
- Las Vegas, NV + 18 other US sites
- Eligibility basics
- Ages 60–90
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Las Vegas, NV + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb
- Location
- Las Vegas, NV + 10 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Las Vegas, NV + 111 other US sites
- Eligibility basics
- Ages 18+